NCT01527643View on ClinicalTrials.gov

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 11, 2003

Primary Completion Date

December 17, 2003

Study Completion Date

December 17, 2003

Conditions

DiabetesHealthy

Interventions

DRUG

biphasic insulin aspart 50

A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss